Last Updated on October 15, 2024 by The Health Master
Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Valbenazine Capsules, 40 mg, 60 mg, and 80 mg, to market a generic equivalent of Ingrezza Capsules, 40 mg, 60 mg, and 80 mg, of Neurocrine Biosciences, Inc.
Valbenazine is indicated for the treatment of tardive dyskinesia (uncontrollable movement of face, tongue, or other body parts).
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of $ 1,235 million in the US. (IQVIA MAT December 2022).
USFDA gives approval for Obeticholic acid tablets
USFDA gives approval for this Antifungal drug
USFDA grants accelerated approval for Skin cancer therapy
USFDA gives approval for Calcipotriene and Betamethasone foam
USFDA gives approval for Brexpiprazole tablets
USFDA gives approval for generic Rocuronium Bromide Injection
CDSCO gives marketing approval for this Diabetes drug in pre-filled pen
Remdesivir not a wonder drug, affects heart: Study
USFDA gives approval for Obeticholic acid tablets
Drug recall: 55,000 bottles of Colchicine tablets due to this reason
Drug Control Dept launches WhatsApp helpline number: Tamil Nadu
Proposal to regulate prices of non-scheduled drugs under consideration
Difference: Disintegration and Dissolution test in pharma industry
How to prepare SOPs in the Pharma Industry
Difference between branded and generic medicines
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
